Abivax shares among the biggest decliners in the SBF 120, down 27.5% over three months
The Paris-based biotech specialising in inflammatory diseases closes the session near the bottom of its index, while the Paris market remains stable. This decline erases part of the gains seen in previous days and extends a very difficult quarter. The stock remains well below its long-term benchmarks.
A 4.12% drop brings the stock back below its 20-day moving average at €79.86
Abivax shares fell 4.12% to €79.10 at the close, compared with €82.50 the previous day. The stock is among the biggest decliners in the SBF 120, while the index gained 0.05%. The stock has dropped back below its 20-day moving average, at €79.86 (a gap of -0.95%), after gaining 1.87% over the week.
The 50-day moving average, at €84.13, is 5.98% above the price, and the 200-day moving average, at €97.98, is 19.27% above. Over three months, the stock has lost 27.63%. This short-term rebound has therefore not reversed the underlying trend.
The support at €76.05 is the closest level in case of a further decline, with resistance at €84.35.
Cumulative short positions reach 5.59% of the share capital
Bearish bets remain high on the stock. According to the disclosures reviewed, five funds hold a combined net short position of 5.59% of the share capital, up 0.23 points over thirty days (5.36% one month ago).
Such a level shows that institutional investors remain positioned for a decline, although this figure says nothing about their motivations.
An increase of this magnitude remains modest over one month. Abivax is a single company listed on two markets: the ordinary share in Paris, eligible for the PEA, and the ADS on the Nasdaq, which represents the same stock. Both lines trade at the same price, and the Nasdaq is the most liquid market.
